MedMira Increases European Sales for Rapid HIV Test - Ships Initial Order to Romania and Follow-On Orders to Existing Distributors



    HALIFAX, Nov. 20 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ:   MMIRF), a global market leader in premium rapid diagnostic solutions,
announced today that it has completed the initial shipment of its MiraCare(TM)
Rapid HIV Antibody Test ("MiraCare HIV") to its newest European distributor,
located in Romania. In addition, MedMira has recently shipped several
follow-on orders to existing European distributors in Germany and The
Netherlands.
    "The increasing sales activity in Europe indicates that our test is
gaining a strong foothold in the marketplace; a direct result of the targeted
efforts put forth by our Sales and Marketing team to build a quality,
high-performance distribution network for this region," said Hermes Chan,
President and CEO of MedMira. "The quality, speed and accuracy of the MiraCare
HIV test is second to none, and we intend to continue our focus on building
towards sustainable sales in this marketplace."
    MiraCare HIV is MedMira's CE-Marked rapid HIV test. Approved for use with
whole blood, as well as serum and plasma specimens, MiraCare HIV is a truly
versatile rapid HIV test for near-patient settings such as pharmacies and
hospitals, as well as laboratories, in Europe. It is sold as a complete test
with all components required to perform the test and provides patient test
results instantly.
    According to the WHO, in 1989, Romania experienced a unique HIV epidemic
in which more than 10,000 institutionalized children contracted HIV through
blood transfusions and infected needles. As a result, Romania probably has the
highest number of HIV infections in central Europe. Over the past 10 years,
the HIV/AIDS incidence rate has continually increased among adults, mainly
related to transmission of the virus via sexual contact and injecting drug
use. The increase in sexual transmission is correlated with a growing
incidence in other STIs particularly syphilis.

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals around the world with reliable, rapid diagnosis for diseases such
as HIV and hepatitis C in just three minutes. The company's tests are sold
under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in
global markets. MedMira's rapid HIV test is the only one in the world to
achieve regulatory approvals in Canada, the United States, China and the
European Union.
    In January 2006, MedMira launched the Maple Biosciences division to
develop and commercialize diagnostic instruments based on two revolutionary
biosensor-based technology platforms. The solutions developed by Maple
Biosciences will enable routine laboratory tests to be performed in a matter
of minutes, increasing laboratory automation, streamlining the diagnosis of
multiple conditions and diseases and positioning MedMira to be a leading
participant in the emerging fields of personalized medicine and molecular
diagnostics. For more information visit www.maplebio.com.
    MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada with a representative office in China. Maples
Biosciences' labs are located in Toronto, Ontario. For more information visit
MedMira's website at www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E




For further information:

For further information: Dr. James Smith, Investor Relations & Corporate
Affairs, (902) 450-1588, ir@medmira.com

Organization Profile

MedMira Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890